1). Matsumoto, T. (1992) Calcium metabolism regulators. Exp. Med., 10, 510–515.
2). Conceição, E.P., Carvalho, J.C., Manhães, A.C., Guarda, D.S., Figueiredo, M.S., Quitete, F.T., Oliveira, E., Moura, E.G. and Lisboa P.C. (2016) Effect of early overfeeding on palatable food preference and brain dopaminergic reward system at adulthood: role of calcium supplementation. J. Neuroendocrinol., 28.
3). Arazi, H., Eghbali, E., Saeedi, T. and Moghadam, R. (2016) The relationship of physical activity and anthropometric and physiological characteristics to bone mineral density in postmenopausal women. J. Clin. Densitom., 19, 382–388.
4). Gerlinger, C., Oster, M., Borgelt, L., Reyer, H., Muráni, E., Ponsuksili, S., Polley, C., Vollmar, B., Reichel, M., Wolf, P. and Wimmers, K. (2019) Physiological and transcriptional responses in weaned piglets fed diets with varying phosphorus and calcium levels. Nutrients, 11.
5). Stewart, T.A. and Davis, F.M. (2019) An element for development: Calcium signaling in mammalian reproduction and development. Biochim. Biophys. Acta. Mol. Cell Res., 1866, 1230–1238.
6). Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC): National Academies Press, 71–145.
7). Pearce, S.H. and Thakker, R.V. (1997) The calcium-sensing receptor: insights into extracellular calcium homeostasis in health and disease. J. Endocrinol., 154, 371–378.
8). Demontiero, O., Vidal, C. and Duque, G. (2012) Aging and bone loss: new insights for the clinician. Ther. Adv. Musculoskelet. Dis., 4, 61–76.
9). Raisz, L.G. (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest., 115, 3318–3325.
10). Azuma, Y. (2007) Animal models of osteoporosis and development of anti-osteoporotic agents. Folia. Pharmacol. Jpn., 130, 201–205.
11). Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney International. 2008;74(2):148–157.
12). Quarles LD, Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118:3820-3828.
13). Segawa H, Aranami F, Kaneko I, Tomoe Y, Miyamoto K. The roles of Na/Pi-II transporters in phosphate metabolism. Bone 2009;45:S2-S7.
14). Suzuki Y, et al；Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update.;2014 update J Bone Miner Metab, 32(4):337-350, 2014
15). Xu Feng Jay M. McDonald Disorders of Bone Remodeling Annu Rev Pathol. 2011 ; 6: 121–145.
16). Iizuka T, Matsukawa M. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. Climacteric. 2008 Aug;11(4):287-95.
17). Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524-31.
18). Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007; 41 (3): 378-85.
19). Michael P. Whyte, M.D., Deborah Wenkert, M.D., Karen L. Clements, R.N., William H. McAlister, M.D., and Steven Mumm, Ph.D :Bisphosphonate- Induced Osteopetrosia. N Engl J Med 2003; 349:457-463.
20). Diab, D, Watts, N. Bisphosphonates drug holidays: who, when and how long. Ther Adv Musculoskel Dis. (2013). (3): 107-111.
21). AACE Postmenopausal Osteoporosis Guidelines, Endocr Pract. 2010;16(Suppl 3)
22). Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K, Shimoi A, Yamatoya H, Yoshida K, Kohira T. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). J Toxicol Sci. 2012;37(3):617-29.
23). Vahle, J.L., Sato, M., Long, G.G., Young, J.K., Francis, P.C., Engelhardt, J.A., Westmore, M.S., Ma, Y.L. and Nold, J.B. (2002): Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 30, 312-321.
24). Vahle, J.L., Long, G.G., Sandusky, G., Westmore, M., Ma, Y.L. and Sato, M. (2004): Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol., 32, 426-438.
25). Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun;21(6):1041-5.
26). Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37.
27). Yamamoto T, Hasegawa T, Sasaki M, Hongo H, Tsuboi K, Shimizu T, Haramachi M, Ota M,Luiz de Freitas PH, Takakura A, Takao-Kawabata R, Isogai Y, Amizuka N. ; Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice. Endocrinology. 2016 July 157(7):2604-2620
28). Joel S. Finkelstein, Jason J. Wyland, Hang Lee, and Robert M. Neer.; Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95(4): 1838–1845.
29). M. Shiraki & T. Sugimoto & T. Nakamura.; Effects of a single injection of teriparatide on bone turnovermarkers in postmenopausal women. Osteoporos Int (2013) 24:219–226
30). Keith A Hruska, Suresh Mathew, and Richard Lund :Osteoporosis and cardiovascular disease: lessons from chronic kidney disease Clin Cases Miner Bone Metab. 2008 Jan-Apr; 5(1): 35–39.
31). Moe S, Drüeke T, Cunningham J, Goodman W,Martin K, Olgaard K, Ott S, SRLague S, Lameire N,Eknoyan G：Kidney Disease：ImRLoving GlobalOutcome（KDIGO）： Definition, evaluation, and classification of renal osteodystrophy：A position statement from Kidney Disease：ImRLoving Global Outcome（KDIGO）. Kidney Int 69：1945-1953, 2006
32). Hruska KA, Mathew S, Lund R, Qiu P, RLatt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74:148-157
33). Komaba H, Goto S, Fujii H et al. Depressed expression of klotho and FGF receptor 1 inhyperplastic parathyroid glands from uremic patients. Kidney Int 2010;77:232-238
34). Komaba H, Goto S, Fujii H et al. DeRLessed exRLession of klotho and FGF receptor 1 inhyperRLastic parathyroid glands from uremic patients. Kidney Int 2010;77:232-238
35). Nagano N, Ando T, Tsutsu Ti et al. A new concept for the pathogenesis of secondary hyperparathyroidism：Pharmacological validation of the trade-off hypothesis and involvementof FGF23／Klotho. J. Jpn. Soc. Dial. Ther. 46_(6)：519〜533，2013
36). Watanabe K, Fujii H, Goto S. Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder. J Atheroscler Thromb. 25: 170–177. 2018.
37). Tani Y, Sato T, Yamanaka-Okumura H, Yamamoto H, Arai H, Sawada H, Genjida K, Taketani Y, Takeda E l. Effects of Prolonged High Phosphorus Diet on Phosphorus and Calcium Balance in Rats. J Clin Biochem Nutr. 40(3): 221–228. 2007.
38). Matsuzaki H, Katsumata S, Uehara M, Suzuki K, Miwa M . High- Phosphorus diet induces osteopontin expression of renal tubules in rats. J Clin Biochem Nutr. 41: 179–183. 2007.
39). VA Aparicio, E Nebot, R García-del Moral, M. Machado-Vílchez3, J. M. Porres1, C. Sánchez1 P. Aranda1. High-protein diets and renal status in rats. Nutr Hosp. 28(1): 232–237. 2013.
40). Atsushi W, Katsuhiro M, Noriko K, Hisashi U, Takayuki A, Hijiri I, Reo A, Dai N. Impact of dietary calcium and phosphorus levels on an ovariectomized Sprague-Dawley rat model of osteoporosis. Fundam. Toxico. Sci. 6(7): 253-258, 2019
41). Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M. Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once- Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097–3106.
42). Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, Krohn KD, Warner MR, Ahmad QI2, Mitlak B. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial. Clin Orthop Relat Res. 2016 May;474(5):1234-44.
43). Yu-Chi Chen1 Donna M Sosnoski. Andrea M Mastro Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010; 12(6): 215.
論文の公開元へ
